Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is the first for schizophrenia in several decades. Cobenfy targets cholinergic receptors instead of balancing levels of dopamine and serotonin, which is what conventional atypical antipsychotics
Read More
Italian autoworkers go on strike, as troubled Stellantis faces pressure over production plans
Workers in Italy’s troubled automotive sector are holding a national strike for the first time in 20 years, with
November 16, 2024
No Comments
